Shire Articles
Stock Commentary - Europe
26 October 2000
Shire files with FDA for SLI 381
5 October 2000
First launch for Shire's Reminyl, in UK
28 September 2000
Yamanouchi sells stake in Shire Pharma
28 September 2000
Novartis rejects Ritalin charges in the USA
19 September 2000
Novartis rejects Ritalin charges in the USA
15 September 2000
Shire reveals once-daily version of Adderall
8 September 2000
Good growth at Shire, Reminyl gets FDA boost
3 August 2000
Shire's US filing of Lambda delayed
3 August 2000
Stock Commentary Europe
27 July 2000
Galantamine approved throughout EU
13 July 2000
Stock Commentary Europe
6 July 2000
Janssen-Cilag gains second EU approval for Reminyl
29 June 2000
Shire opening subsidiary in Spain
7 June 2000
Shire's Fareston shows equivalence to tamoxifen
25 May 2000
Shire opens Singapore office
4 May 2000
Stock Commentary Europe and London
4 May 2000
Shire and Cortex link up for ADHD
26 April 2000
Shire's pretax profits climb 40% in 1st qtr
26 April 2000
Stock Commentary Europe
19 April 2000
Sanochemia developing "improved" galantamine
12 April 2000
Shire presents positive data with Reminyl
7 April 2000
D-Pharm and Shire link up for epilepsy compound
16 March 2000
Stock Commentary Europe
9 March 2000
Merger with Roberts going smoothly at Shire as revenues rise 30%
29 February 2000
Stock Commentary Europe
24 February 2000
Stock Commentary Europe
17 February 2000
Stock Commentary Europe
27 January 2000
Shire/Roberts merger close to completion
25 November 1999
$280 million life sciences fund set up
1 November 1999
Stock Commentary Europe
28 October 1999
Shire profits leap, now looking at Europe
21 October 1999
AnorMED begins Phase III with Lambda
21 October 1999
Shire and NeuroSearch begin Phase I with stroke drug
14 October 1999
Shire files NDA for galantamine
11 October 1999
Shire signs manufacturing agreement with Catalytica
16 September 1999
Medeva shares jump on merger talks
9 September 1999
Stock Commentary Europe
29 July 1999
Stock Commentary New York
29 July 1999
Stock Commentary Europe
22 July 1999
Medeva profits take a battering
21 July 1999
Alternative delivery mkt set for fast growth
12 July 1999
Shire's Lambda to enter Phase III in USA
25 June 1999
Shire benefits from strong US growth
13 May 1999
Janssen files first dossier for galantamine
8 April 1999
Shire profits grow despite Arenol bomb
16 March 1999
Meconic opium probe - a threat to galantamine FDA clearance?
5 February 1999
Shire set to divest US manufacturing plant
18 January 1999
Galantamine still on target for 1Q99 filing
11 January 1999
Advances In CNS Therapeutics Reviewed By Lehman Analysts
30 November 1998
Shire Relatively Happy With 3rd Qtr
23 November 1998
Nigel Atherton New Director of Project Management at Shire
12 November 1998
UK Biotech Firms Back In Vogue With Investors?
5 November 1998
Shire Restarts Adderall Supplies
28 October 1998
Shire Pharmaceuticals Arrange ADD Drug Ingredients Supply
3 September 1998
Neurosearch Has Five Products In Clinical Development
1 September 1998
Progress For Shire On Restarting ADHD Supplies
1 September 1998
Shire Pharmaceuticals Appoints Medical Director
20 August 1998
Explosion At Arenol To Hit Shire Profits In 4th Qtr
18 August 1998
Explosion Impacts Shire Products
6 August 1998
Stock Commentary Europe
23 July 1998
Appointment At Shire
25 June 1998
Phase III Data With Hyal/Shire's HyClinda
18 June 1998
Dramatic Growth Seen In Europe's Biotech Sector
4 June 1998
Shire Launches Carbatrol
30 April 1998
Drugs And Media: Making And Controlling The News
3 April 1998
Shire Public Offering Raises L20 Mill
2 April 1998
Shire Files For Public Offering
5 March 1998
Appointment At Shire
12 February 1998
Developments At Denmark's NeuroSearch
9 February 1998
Appointment At Shire
5 February 1998
Majors Moving Away From Acquisitions & Mergers
12 January 1998
Hyal Product Setback Cuts Investor Confidence
12 January 1998
Majors Moving Away From Acquisitions & Mergers
6 January 1998
Carbatrol Agreement Redrawn
29 December 1998
Appointment at Shire Labs
27 November 1997
Shire And Novo Nordisk: Epilepsy Drugs Cleared
16 October 1997
Shire Files IND For Aciclovir Formulation
15 October 1997
Shire Results Signal "Year Of Significant Achievement"
18 September 1997
Shire To Launch Suprecur Injection
28 August 1997
Appointment At Shire
28 August 1997
Focus On Exelon For Alzheimer's Disease
14 August 1997
European and London Stock Comment
7 August 1997
Appointment At NitroMed
7 August 1997
Shire To Merge With Richwood In $186m Takeover
6 August 1997
Shire And Janssen Acquire Galantamine Rights
9 June 1997
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
